1. Triiodothyronine (T3) upregulates the expression of proto-oncogene TGFA independent of MAPK/ERK pathway activation in the human breast adenocarcinoma cell line, MCF7.
- Author
-
Silva TM, Moretto FCF, Sibio MT, Gonçalves BM, Oliveira M, Olimpio RMC, Oliveira DAM, Costa SMB, Deprá IC, Namba V, Nunes MT, and Nogueira CR
- Subjects
- Adenocarcinoma metabolism, Breast Neoplasms metabolism, Cell Line, Tumor metabolism, Female, Humans, MCF-7 Cells metabolism, Proto-Oncogene Mas, Proto-Oncogenes genetics, RNA, Messenger genetics, Transforming Growth Factor alpha drug effects, Transforming Growth Factor alpha metabolism, Triiodothyronine metabolism, Triiodothyronine pharmacology, Adenocarcinoma genetics, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic genetics, MAP Kinase Signaling System genetics, Transforming Growth Factor alpha genetics, Triiodothyronine genetics
- Abstract
Objective: To verify the physiological action of triiodothyronine T3 on the expression of transforming growth factor α (TGFA) mRNA in MCF7 cells by inhibition of RNA Polymerase II and the MAPK/ERK pathway., Materials and Methods: The cell line was treated with T3 at a physiological dose (10-9M) for 10 minutes, 1 and 4 hour (h) in the presence or absence of the inhibitors, α-amanitin (RNA polymerase II inhibitor) and PD98059 (MAPK/ERK pathway inhibitor). TGFA mRNA expression was analyzed by RT-PCR. For data analysis, we used ANOVA, complemented with the Tukey test and Student t-test, with a minimum significance of 5%., Results: T3 increases the expression of TGFA mRNA in MCF7 cells in 4 h of treatment. Inhibition of RNA polymerase II modulates the effect of T3 treatment on the expression of TGFA in MCF7 cells. Activation of the MAPK/ERK pathway is not required for T3 to affect the expression of TGFA mRNA., Conclusion: Treatment with a physiological concentration of T3 after RNA polymerase II inhibition altered the expression of TGFA. Inhibition of the MAPK/ERK pathway after T3 treatment does not interfere with the TGFA gene expression in a breast adenocarcinoma cell line.
- Published
- 2019
- Full Text
- View/download PDF